Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke. (Funded by Eli Lilly; SURPASS-CVOT ClinicalTrials.gov number, NCT04255433.).
Authors
- A. Michael Lincoff (ORCID: https://orcid.org/0000-0001-8175-2121)
- Debra L. Miller (ORCID: https://orcid.org/0000-0002-8544-174X)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Alan Herschtal (ORCID: https://orcid.org/0000-0001-9247-5609)
- Linong Ji (ORCID: https://orcid.org/0000-0002-3262-2168)
- Stefano Del Prato (ORCID: https://orcid.org/0000-0002-5388-0270)
- Russell J. Wiese (ORCID: https://orcid.org/0009-0007-6705-7545)
- Imre Pávó (ORCID: https://orcid.org/0000-0002-2016-7049)
- Sophia Zoungas (ORCID: https://orcid.org/0000-0003-2672-0949)
- Monika Kellerer (ORCID: https://orcid.org/0000-0002-9834-5976)
- John B. Buse (ORCID: https://orcid.org/0000-0002-9723-3876)
- Steven E. Nissen (ORCID: https://orcid.org/0000-0002-7231-6464)
- Jonathan Broder (ORCID: https://orcid.org/0000-0003-0776-1278)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Venu Menon (ORCID: https://orcid.org/0000-0003-4410-2677)
- Francesco Giorgino (ORCID: https://orcid.org/0000-0001-7372-2678)
- Hiroshi Nishiyama (ORCID: https://orcid.org/0000-0001-5034-5777)
- Steven E. Kahn (ORCID: https://orcid.org/0000-0001-7307-9002)
- Michael A. Nauck (ORCID: https://orcid.org/0000-0002-5749-6954)
- David A. D’Alessio (ORCID: https://orcid.org/0000-0003-4155-4870)
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Tamás Várkonyi (ORCID: https://orcid.org/0000-0003-2057-7993)
- Naveed A. Sattar (ORCID: https://orcid.org/0000-0002-1604-2593)
- Bernard Zinman (ORCID: https://orcid.org/0000-0002-0041-1876)
- Melanie J Davies
- Govinda Weerakkody (ORCID: https://orcid.org/0009-0003-0068-1897)
- Jan Basile
Institutions
- University of North Carolina at Chapel Hill (US)
- Parkland Health & Hospital System (US)
- Cleveland Clinic (US)
- Medical University of South Carolina (US)
- University of Leicester (GB)
- Scuola Superiore Sant'Anna (IT)
- Eli Lilly (United States) (US)
- University of Toronto (CA)
- Peking University (CN)
- Lunenfeld-Tanenbaum Research Institute (CA)
- University of Szeged (HU)
- Universitätsmedizin Greifswald (DE)
- Cleveland Clinic Lerner College of Medicine (US)
- VA Puget Sound Health Care System (US)
- Marienhospital Stuttgart (DE)
- Mount Sinai Hospital (US)
- Peking University People's Hospital (CN)
- University Children's Hospital Tübingen (DE)
- Duke Medical Center (US)
- Ralph H. Johnson VA Medical Center (US)
- Katholisches Klinikum Bochum (DE)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Bari Aldo Moro (IT)
- Monash University (AU)
- University of Glasgow (GB)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1056/nejmoa2505928
- Citations
- 26
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 33.67